Aliqopa (copanlisib) vs Lunsumio (mosunetuzumab-axgb)

Aliqopa (copanlisib) is a kinase inhibitor specifically designed to target and inhibit the phosphatidylinositol 3-kinase (PI3K) pathway, which is known to be involved in the growth and survival of certain cancer cells; it is approved for the treatment of adult patients with relapsed follicular lymphoma. Lunsumio (mosunetuzumab-axgb), on the other hand, is a bispecific T-cell engager antibody that binds to both CD20 on B cells and CD3 on T cells, thereby redirecting T cells to engage and eliminate B-cell lymphoma cells; it is used for the treatment of relapsed or refractory follicular lymphoma. When deciding between the two, a patient should consider factors such as the mechanism of action, the side effect profile, and the specific indications and recommendations of their healthcare provider, as these medicines have different approaches to treating lymphoma and may not be interchangeable.

Difference between Aliqopa and Lunsumio

Metric	Aliqopa (copanlisib)	Lunsumio (mosunetuzumab-axgb)
Generic name	copanlisib	mosunetuzumab-axgb
Indications	Relapsed follicular lymphoma	Relapsed or refractory follicular lymphoma and other non-Hodgkin lymphomas
Mechanism of action	PI3K inhibitor	Bispecific CD20-directed CD3 T-cell engager
Brand names	Aliqopa	Lunsumio
Administrative route	Intravenous	Intravenous
Side effects	Hyperglycemia, hypertension, neutropenia, etc.	Cytokine release syndrome, infections, fatigue, etc.
Contraindications	None known specifically; use caution in patients with severe hepatic impairment or with active, serious infections.	None known specifically; use caution in patients with active, serious infections, and those with a history of severe allergic reactions to monoclonal antibodies.
Drug class	Antineoplastic agent, PI3K inhibitor	Antineoplastic agent, bispecific monoclonal antibody
Manufacturer	Bayer	Genentech

Efficacy

Aliqopa (Copanlisib) Efficacy in Treating Lymphoma

Aliqopa (copanlisib) is a kinase inhibitor specifically designed to target and inhibit the phosphoinositide 3-kinase (PI3K) pathway, which is known to play a significant role in the growth and survival of many cancer cells, including those in certain types of lymphoma. The efficacy of Aliqopa in treating lymphoma was demonstrated in a pivotal study that led to its accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies.

In clinical trials, Aliqopa showed a significant response rate in patients with relapsed follicular lymphoma. The overall response rate (ORR) was observed to be substantial, with some patients achieving complete responses (CR), indicating the complete disappearance of all signs of cancer in response to the treatment. The duration of response (DOR) for those who responded to Aliqopa was also clinically meaningful, with a proportion of patients maintaining their response for at least six months.

Lunsumio (Mosunetuzumab-axgb) Efficacy in Treating Lymphoma

Lunsumio (mosunetuzumab-axgb) is a bispecific antibody that targets CD20 on B cells and CD3 on T cells, bringing these two cell types into close proximity and thereby promoting the destruction of malignant B cells. It is being developed for the treatment of various types of non-Hodgkin lymphoma (NHL), including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Lunsumio has shown promise in early clinical trials, particularly for patients with relapsed or refractory forms of the disease.

In a phase I/II clinical trial, mosunetuzumab-axgb demonstrated a high rate of complete responses in patients with relapsed or refractory B-cell lymphomas, including those who had previously undergone multiple lines of therapy or were considered difficult to treat. The ORR and CR rates reported in these studies suggest that Lunsumio could provide a new therapeutic option for patients with limited treatment choices. Additionally, the DOR for responders was notable, with many patients maintaining their response over an extended period, which is particularly encouraging for a population with historically poor prognoses.

Regulatory Agency Approvals

Aliqopa

Food and Drug Administration (FDA), USA

Lunsumio

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Aliqopa or Lunsumio today

If Aliqopa or Lunsumio are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Aliqopa

Buy Lunsumio

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: